Remove 2018 Remove Documentation Remove Medical Records
article thumbnail

The unsustainability of clinical trials and need for transformative change

Pharmaceutical Technology

The rising volume of clinical trials increases demand and competition for patients The number of oncology assets in the clinical development pipeline has increased by 13% annually over five years (2018-2022) 1. On paper, this sounds like a positive time for medical innovation. Sign up for our daily news round-up!

article thumbnail

Five Lessons Learned About Antimicrobial Stewardship Metrics

IDStewardship

It may be derived from work completed inthe microbiology lab, unitsdispensed from the pharmacy, administrations performed by nurses, expenditures produced from drug purchases, documentation within any area of the electronic medical record, extraction from supplemental tools or data warehouses, and so much more.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

When Worlds Collide: The Theory of Real-World Evidence Meets Reality

The FDA Law Blog

RWD can be collected from a wide range of sources, such as electronic health records, registries, administrative claims, pharmacy data, and feedback from wearables and mobile technology. In fact, in 2018, FDA emphasized that leveraging the use of RWD and RWE in regulatory decision-making is “a top strategic priority for the FDA.”

FDA
article thumbnail

Adherence to NICE criteria for initiation and continuation of treatment with a biologic in atopic dermatitis

Hospital Pharmacy Europe

Dermatology correspondence (as part of the medical record) were examined as far back as 2012 if necessary for relevant information about patients’ treatment. TA534, August 2018. Relevant data (patient demographics and treatment details) were imported into Excel by a member of the pharmacy team. Conclusion. References.